Quantum BioPharma Ltd. (CSE:QNTM)
Canada
· Delayed Price · Currency is CAD 7.40
+1.31 (21.51%)
At close: Apr 28, 2026
Quantum BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Selling, General & Admin | 9.05 | 9.41 | 9.03 | 14.45 | 15.93 | Upgrade
|
| Research & Development | 2.76 | 6.08 | 3.86 | 6.91 | 6.33 | Upgrade
|
| Operating Expenses | 15.3 | 16.14 | 19.23 | 27.43 | 33.74 | Upgrade
|
| Operating Income | -15.3 | -16.14 | -19.23 | -27.43 | -33.74 | Upgrade
|
| Interest Expense | -2.11 | -0.05 | -0 | -0.05 | -0.07 | Upgrade
|
| Interest & Investment Income | 0.24 | 0.57 | 0.79 | 0.37 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -12.61 | -0.03 | 0.21 | 0.52 | 0.68 | Upgrade
|
| EBT Excluding Unusual Items | -29.78 | -15.64 | -18.24 | -26.59 | -33.13 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.43 | -0 | -0.38 | -0.23 | -0.86 | Upgrade
|
| Asset Writedown | - | - | -4.56 | - | - | Upgrade
|
| Legal Settlements | 2.35 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.04 | 0.73 | 4.94 | 0.12 | 0.05 | Upgrade
|
| Pretax Income | -26.96 | -14.92 | -18.23 | -26.7 | -33.94 | Upgrade
|
| Earnings From Continuing Operations | -26.96 | -14.92 | -18.23 | -26.7 | -33.94 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 3.1 | -1.35 | Upgrade
|
| Net Income to Company | -26.96 | -14.92 | -18.23 | -23.61 | -35.29 | Upgrade
|
| Minority Interest in Earnings | 0.78 | 0.71 | 0.33 | - | - | Upgrade
|
| Net Income | -26.18 | -14.2 | -17.9 | -23.61 | -35.29 | Upgrade
|
| Net Income to Common | -26.18 | -14.2 | -17.9 | -23.61 | -35.29 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 189.01% | 86.67% | 2.21% | 10.84% | 190.15% | Upgrade
|
| EPS (Basic) | -7.97 | -12.49 | -29.39 | -39.62 | -65.63 | Upgrade
|
| EPS (Diluted) | -7.97 | -12.49 | -29.39 | -39.62 | -65.63 | Upgrade
|
| Free Cash Flow | -8.24 | -6.88 | -10.83 | -28.45 | -20.75 | Upgrade
|
| Free Cash Flow Per Share | -2.51 | -6.05 | -17.78 | -47.74 | -38.59 | Upgrade
|
| EBITDA | -14.76 | -15.65 | -16.73 | -22.9 | -29.7 | Upgrade
|
| D&A For EBITDA | 0.55 | 0.49 | 2.51 | 4.53 | 4.05 | Upgrade
|
| EBIT | -15.3 | -16.14 | -19.23 | -27.43 | -33.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.